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Heart Rate Variability and Length of Survival in Hospice Cancer 
Patients 
We examined the association between heart rate variability (HRV) and survival duration to 
evaluate the usefulness of HRV as a prognostic factor for hospice cancer patients. In 
terminally ill cancer patients who visited the Hospice clinic, we checked demographic data, 
Karnofsky performance scale (KPS), HRV, dyspnea, anorexia, as well as fasting blood glucose 
and total cholesterol. After following up their duration of survival, we examined 
meaningful prognostic factors for predicting life expectancy through the survival analysis. 
A total of 68 patients were included in final analysis. As KPS was lower, or when combined 
with dyspnea or anorexia, the survival duration was much shorter. HRV parameters except 
heart rate were all impaired in most patients. In particular, the group with mean heart rate 
of 100 or more beats per minute and the group with standard deviations of normal-to-
normal R-R intervals (SDNN) of 21.3 ms (75 percentile) or less showed significantly shorter 
survival duration. The final multivariate analysis adjusting for age, gender, fasting blood 
glucose, and total cholesterol showed that KPS, dyspnea, anorexia, and SDNN were 
significant prognostic factors in survival duration. For the first time, we report that SDNN is 
a prognostic factor in terminal cancer patients. 
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INTRODUCTION 
Cancer incidence rates and the number of cancer-related deaths 
continue to increase despite medical developments. In Korea, 
the number of deaths due to cancer went up from 51,449 in 1998 
to 68,912 in 2008, and cancer has now become the leading cause 
of death in Korea (1). In particular, a high level of in-hospital mor-
tality among terminal cancer patients is raising ethical issues as 
many patients die alone in hospitals, surrounded by medical 
equipment instead of family and friends, and the financial bur-
den associated with increasing medical costs (2). Thus, more 
countries are adopting hospice and palliative care programs, 
and hospice services are being globally recognized as a means 
of improving quality of life and of reducing medical costs in ter-
minal cancer patients (3-5). However, despite the advantages of 
hospice care, decision-making concerning eligibility for hospice 
care is problematic. In general, patients with less than six months 
to live with an underlying incurable disease are considered eli-
gible for hospice care. However, in reality, as previous studies 
have reported, many predictions made by medical practitioners 
concerning time to death tend to be optimistic in terminal can-
cer patients (6, 7). As a result, many patients are not offered hos-
pice care in a timely manner (8). Accordingly, the issue of accu-
rately determining life span in terminal cancer patients is of great 
concern to patients, their caregivers, doctors, and policymakers. 
  Heart rate variability (HRV) is used in clinical research be-
cause fetal distress is preceded by alterations in the R-R inter-
val. HRV reflects autonomic neuropathy in diabetic patients and 
predicts mortality in myocardial infarction patients (9-11). HRV 
also predicts mortality in cases of heart failure, cardiomyopathy, 
and renal failure; and HRV also predicts sudden death and car-
diac death in apparently healthy individuals (12-16). Autonomic 
dysfunction is commonly associated with terminally ill cancer 
patients (17). Accordingly, we studied the relationship between 
HRV and survival duration to evaluate the usefulness of HRV as 
a prognostic factor for terminally ill cancer patients. 
MATERIALS AND METHODS
Patients
Recruitment of potential subject was conducted from March 1, 
2004, to August 31, 2006, among patients with terminal cancer. 
They were referred to the Department of Family Medicine at 
Korea University Guro-Hospital for hospice care after antican-
cer-therapy had proven ineffective. We consecutively enrolled 
patients who were eligible for HRV testing and agreed to partic-
ipate in this study. Patients with arrhythmia or a cardiac disor-
der capable of affecting HRV parameters, such as paroxysmal Kim DH, et al.  •  Heart Rate Variability and Length of Survival
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supraventricular tachycardia, atrial fibrillation, recent myocar-
dial infarction, or myocardial ischemia, were excluded. Patients 
who were unable to maintain a stable supine posture for 5 min 
were also excluded. Finally, a total of 70 patients were enrolled 
and we observed their survival duration until death. However, 
two patients were lost to follow up. Thus, 68 patients were includ-
ed in the final analysis. 
Data acquisition
Demographic variables were gender, age, primary cancer site, 
and previous treatment method. The Karnofsky performance 
status scale (KPS) and the presence of anorexia and dyspnea, 
which are parametric constituents of the palliative prognostic 
score (PaP), were also determined. In previous studies, fasting 
blood glucose (FBG) and total cholesterol were found to affect 
HRV (18-21). Therefore, we checked FBG and total cholesterol 
level, which were measured within one week before and after 
HRV test. After agreeing to participate in this study, the short 
term HRV was measured over five minutes using an HRV ana-
lyzer, BFM-5000 Plus (Medi-Core Co. Ltd., Seoul, Korea). By us-
ing time-domain analysis, mean heart rates, standard devia-
tions of normal-to-normal R-R intervals (SDNN), and root mean 
square standard deviations of R-R intervals (RMSSD) were cal-
culated. Frequency-domain analysis was applied to measure 
5-min total power (TP), low frequency power (LFP), and high 
frequency power (HFP). HRV parameters were measured by the 
recommendations published by the Task Force of The European 
Society of Cardiology and The North American Society of Pacing 
and Electrophysiology in 1996 (22). The HRV test was explained 
to patients in a quiet, pleasant medical office and conducted 
over 5 min after applying four limb leads. Patients were advised 
not to smoke or consume caffeine for 2 hr prior to HRV testing, 
and tests were conducted more than 2 hr after a meal. Survival 
duration was defined from HRV testing until the date of death. 
This study was approved by the Institutional Review Board (IRB) 
of Korea University Guro Hospital (IRB No. GR0514-002). 
Statistical analysis
Univariate analysis of log-rank test for categorical variables or 
Wald test for continuous variables were performed to identify 
variables that significantly related to survival duration. The re-
lationship between HRV measures and the variables related to 
HRV, fasting blood glucose and total cholesterol, was examined 
using correlation analysis. Finally, Cox’s proportional hazard 
regression model was used to determine the effects of dyspnea, 
anorexia, KPS, mean heart rates, and SDNN, which were signif-
icant in univariate analysis, on survival duration after adjusting 
for gender, age, fasting blood glucose, and total cholesterol. All 
tests were two-tailed with 5% level of significance. SAS version 9.1 
(SAS Institute Cary, NC, USA) was used for statistical analysis.
RESULTS
Basic statistics and HRV
We analyzed 68 patients (34 men and 34 women) aged between 
26 and 84 yr old. The most common primary cancer sites were: 
lung (20.6%), stomach & esophagus (14.7%), hepatobiliary (14.7 
%), gynecologic (13.2%), and colorectal (10.3%). Previous treat-
ment types were (in descending order) surgery+chemotherapy 
(29.4%), no treatment (19.1%), chemotherapy (14.7%), surgery+
chemotherapy+radiotherapy (11.8%), and chemotherapy+radio- 
therapy (11.8%) (Table 1). The distribution of HRV parameters 
are described in Table 2. HRV levels were considerably lower than 
the general Korean population except mean heart rate (23).
Clinical parameters and survival duration
Gender, age, fasting blood glucose, and total cholesterol were 
independent of survival duration (P=0.584, 0.064, 0.421, 0.467, 
respectively). However, patients with higher KPS survived lon-
ger than those with lower scores (P<0.001). Patients with symp-
toms of dyspnea or anorexia had shorter survival durations than 
those without symptoms (P=0.037, 0.015, respectively). Fig. 1A-C 
showed Kaplan-Meier Survival curves of groups subdivided by 
these clinical parameters.
Table 1. Demographic characteristics of study population (N=68)
Characteristics No. (%)
Sex
   Male
   Female
34 (50)
34 (50)
Age (yr)
   <40
   40-59
   60-79
   ≥80
3 (4.4)
32 (47.1)
30 (44.1)
3 (4.4)
Primary cancer site
   Stomach & Esophagus 
   Colorectal
   Pancreas
   Hepatobiliary
   Prostate & Bladder
   Lung
   Breast
   Gynecologic (Uterus, Cervix, Ovary)
   Head & Neck
   Others
   Unknown
10 (14.7)
  7 (10.3)
3 (4.4)
10 (14.7)
3 (4.4)
14 (20.6)
2 (2.9)
  9 (13.2)
2 (2.9)
  7 (10.3)
1 (1.5)
Previous treatment
   Surgery only
   CTx
   RTx
   Surgery+RTx
   Surgery+CTx
   CTx+RTx
   Surgery+CTx+RTx
   None
1 (1.5)
10 (14.7)
4 (5.9)
4 (5.9)
20 (29.4)
  8 (11.8)
  8 (11.8)
13 (19.1)
CTx, chemotherapy; RTx, radiotherapy. Kim DH, et al.  •  Heart Rate Variability and Length of Survival
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Fasting blood glucose, total cholesterol, and HRV
Correlation analysis between HRV parameters and fasting blood 
glucose or total cholesterol showed that all of the HRV parame-
ters except mean heart rate were significantly correlated with 
total cholesterol (for SDNN, correlation coefficients 0.43, P< 
0.001).
HRV and survival duration
As in previous studies on the association between HRV and prog-
nosis, patients were dichotomized by the highest quartile (75%) 
of each HRV parameter (11, 14-16). However, 100 beats per min 
(bpm) was adopted as the reference level for grouping by mean 
heart rate because it is generally accepted as the definition of 
Table 2. Distribution of HRV parameters (N=68)
Parameters Mean heart rate (bpm) SDNN (ms) RMSSD (ms) TP (ms
2) LFP (ms
2) HFP (ms
2)
Mean±SD 94.5±18.2 17.9±13.5 13.8±11.8 365.5±669.9 103.2±257.6 49.4±108.2
Median 93.000 14.400 11.35 136.750 20.750 17.100
Minimum 52  3.5 2 1.2 0.1 0.1
Maximum 142 57.7  71.8 3,396.5 1,758.0 839.7
Quartile
   25
   50
   75
84.500
93.000
104.375
8.625
14.4
21.3
5.325
11.35
16.975
39.25
136.75
358.425
6.975
20.75
100.3
4.3
17.1
62.4
HRV, heart rate variability; SDNN, standard deviations of normal-to-normal R-R intervals; RMSSD, root mean square standard deviations of R-R intervals; TP, total power; LFP, 
low frequency power; HFP, high frequency power; bpm, beat per minute; ms, millisecond.
Fig. 1. Kaplan-Meier survival curves (n=68). (A) Karnofsky performance status scale* (P<0.001). (B) Anorexia (P=0.015). (C) Dyspnea (P=0.037). (D) Mean heart rate 
(dichotomized by 100 bpm). (E) SDNN (dichotomized by quartile 3, 21.3 msec). 
*KPS variable was grouped according to the reference level of palliative prognostic score. 
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
Length of survival (days)
Length of survival (days)
Length of survival (days)
Length of survival (days)
Length of survival (days)
0  100  200  300  400  500  600
0  100  200  300  400  500  600
0  100  200  300  400  500  600
0  100  200  300  400  500  600
0  100  200  300  400  500  600
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
1.0
0.8
0.6
0.4
0.2
0.0
A
D
B 
E 
C
Anorexia=No
Anorexia=Yes
Karnofsky performance status scale=10-20
Karnofsky performance status scale ≥30
Mean heart rate <100
Mean heart rate ≥100
SDNN <21.3
SDNN ≥21.3
Dyspnea=No
Dyspnea=Yes
Table 3. Univariate analysis of survival duration for dichotomized HRV parameters 
(N=68)
Variables Subdivision of groups P value
†
Mean heart rate <100/min ≥100/min 0.003
SDNN <21.3 msec ≥21.3 msec 0.012
RMSSD <16.975 msec ≥16.975 msec 0.726
TP <358.425 msec
2 ≥358.425 msec
2 0.076
LFP <100.3 msec
2 ≥100.3 msec
2 0.243
HFP <62.4 msec
2 ≥62.4 msec
2 0.778
LFP/HFP <3.345  ≥3.345  0.658
*HRV parameters were dichotomized about the highest quartile; 
†Log-rank test.
HRV, heart rate variability; SDNN, standard deviations of normal-to-normal R-R intervals; 
RMSSD, root mean square standard deviations of R-R intervals; TP, total power; LFP, 
low frequency power; HFP, high frequency power.Kim DH, et al.  •  Heart Rate Variability and Length of Survival
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tachycardia. Subsequently, significant differences in survival 
duration were found between patients with an SDNN of <21.3 ms 
or ≥21.3 ms and between patients with mean heart rate of <100 
bpm or ≥100 bpm (Table 3). Fig. 1D, E showed Kaplan-Meier 
survival curves of patients dichotomized on mean heart rate 
and SDNN, respectively. For HRV parameters other than SDNN 
and mean heart rate, survival durations after dichotomization 
were not significantly different.  
Multivariate regression analysis using Cox’s proportional 
hazard model
To identify factors associated with survival duration among all 
variables examined, we performed multivariate regression anal-
ysis using Cox’s proportional hazard model. The final model in-
cluded gender, age, fasting blood glucose, total cholesterol, KPS, 
dyspnea, anorexia, mean heart rate, and SDNN. In addition to 
these variables, we added an interaction variable (inter= Chole- 
sterol×SDNN) to the final regression model because total cho-
lesterol level was significantly correlated with SDNN, indicating 
a possible interaction. Finally, SDNN, KPS, the interaction vari-
able, dyspnea, and anorexia were significant variables by Back-
ward selection (Table 4).
DISCUSSION
When faced with the reality that anticancer treatment is no lon-
ger effective, the patient and his or her family as well as health 
professionals are faced with a number of difficult decisions; for 
example, breaking bad news about prognosis, complications of 
treatment associated with progressive cancer, ect. One of most 
difficult questions put to doctors by cancer patients and their 
families is likely to be patient’s survival duration (24, 25). The 
question is very important to the patient or family members, 
because knowledge of time remaining might help a patient spend 
the time more effectively and meaningfully. Therefore, an accu-
rate estimation of survival duration may help patients and their 
families resolve conflicts and better cope with emotional issues. 
Not surprisingly, such considerations have prompted many stud-
ies on predicting survival duration in terminal cancer patients. 
  The KPS is a common method to objectively quantify the abil-
ity to perform daily activities in cancer patients and is essential 
for predicting survival duration. We also found that KPS was a 
significant predictor of survival duration. Patients with difficulty 
to perform daily activities generally have only a short time to 
live. However, a good ability to perform daily activities does not 
necessarily mean longer survival (26). The palliative prognostic 
score (PaP) also proved a useful tool for survival prediction, and 
has been used to estimate 30 day survival probability based on 
doctors’ clinical prediction, clinical manifestations (dyspnea, 
anorexia, KPS), and blood count (the number of white blood 
cells and lymphocyte fraction) (27, 28). In our study, dyspnea, 
anorexia, and KPS were all significant prognostic factors of sur-
vival duration. Fasting blood glucose and total cholesterol were 
checked due to their relationship with heart rate variability, but 
they didn’t effect on survival duration in univariate analysis. On 
the other hand, relatively high correlations were found between 
total cholesterol and HRV parameters (except mean heart rate), 
implying interactions between these variables in multivariate 
analysis. 
  HRV tests are objective, non-invasive, and quantitative tools 
for assessing changes in cardiac autonomic nervous activity. 
HRV is calculated from variations in beat-to-beat (R-R) intervals, 
which are controlled by the parasympathetic and sympathetic 
nervous systems. These activities change according to internal 
and external stimuli if they are normal. However, HRV decreas-
es if the autonomic nervous system is impaired (22). Along with 
traditional time-domain analysis, frequency-domain analysis 
based on power spectrum analysis, which began to attract atten-
tion in the early 1980s, has been used to measure HRV. In fre-
quency-domain analysis, R-R heartbeat intervals are altered by 
breathing, baroreceptor reflex, renin-angiotensin-aldosterone 
system, vasomotor activity, and parasympathetic and sympa-
thetic activities, the latter of which generates impulses of con-
stant frequency. When determining R-R intervals associated with 
these specific impulses by power spectrum analysis, parasym-
pathetic and sympathetic nervous activities can be classified 
and quantified (10, 22). 
  After HRV parameters were found to be a significant prognos-
tic factor in patients with myocardial infarction, many studies 
were conducted to determine whether HRV parameters can pre-
dict mortality in other disorders (11, 13-16). We tested the use-
fulness of HRV parameters in terms of predicting survival dura-
tion in terminally ill cancer patients. Survival analyses were per-
formed by dichotomizing patients using specific levels, namely 
Table 4. Multivariate analysis using Cox's proportional hazard model to identify factors associated with survival duration (N=54)
Variables Parameter estimate Standard error Hazard ratio
95% Hazard ratio
confidence limits
P value
Karnofsky scale -0.99854 0.35907   0.368 0.182   0.745   0.005
Dyspnea  0.87627 0.34194   2.402 1.229   4.695 0.01
Anorexia  0.95624 0.40461   2.602 1.177 5.75   0.018
SDNN -2.77822 1.21511   0.062 0.006   0.673   0.022
Inter  0.01042 0.00488 1.01 1.001 1.02   0.033
SDNN, standard deviations of normal-to-normal R-R intervals; Inter, SDNN×total cholesterol.Kim DH, et al.  •  Heart Rate Variability and Length of Survival
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the highest quartiles of HRV measures to conduct the Kaplan-
Meier survival analysis. Mean heart rate and SDNN were signif-
icantly related to survival duration in univariate analysis (Table 
3). Final multivariate regression analysis was performed using 
Cox’s proportional hazard model by adjusting for gender, age, 
fasting blood glucose level and total cholesterol level, and con-
sidering KPS, dyspnea, anorexia, mean heart rate, and SDNN. 
There was high correlation between total cholesterol and SDNN, 
which could lead to an interaction. Therefore, we considered an 
interaction variable between total cholesterol and SDNN in the 
final regression model. Consequently, SDNN, KPS, dyspnea, an-
orexia, and the interaction variable were all significant variables 
(Table 4). These results suggest that HRV is impaired in most ter-
minal cancer patients and SDNN could be useful to predict sur-
vival duration in terminal cancer patients. Heart rate is associ-
ated with survival duration in terminally ill cancer patients (29). 
We also verified a similar result in univariate analysis. 
  This study was conducted at a single medical institution in 
Korea and is therefore preliminary data for Korean hospice can-
cer patients. Furthermore, if all palliative prognostic score (PaP) 
variables including doctor’s clinical prediction, white blood cell 
count, and lymphocyte fraction could be evaluated, we could 
discover more interesting facts as to whether HRV can improve 
the prediction power of PaP as prognostic factor. 
  To our knowledge, this is the first study to suggest that SDNN 
can play a role in survival prediction for terminal cancer patients. 
As the short-term HRV test is a simple, non-invasive, objective, 
and quantitative tool, it has advantages over other prognostic 
factors. Future work is needed to verify the usefulness and char-
acter of SDNN for predicting survival duration in terminally ill 
cancer patients.
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